Division of Hematology/Oncology, Northwestern University, Chicago, IL 60611, USA.
Expert Rev Anticancer Ther. 2011 Oct;11(10):1555-65. doi: 10.1586/era.11.125.
Systemic chemotherapy for advanced pancreatic cancer is commonly used in practice; however, the optimal strategy for both neoadjuvant and adjuvant therapy in this disease remains controversial. A particular challenge remains in patients who are considered to be locally advanced and either unresectable or borderline resectable. Offering optimal neoadjuvant therapy to this group of patients may give them the opportunity to have a curative surgical approach. This article will discuss the potential role of neoadjuvant therapy in borderline, potentially resectable pancreatic cancer. It will also discuss areas of interest in potential targets as the biology of pancreatic adenocarcinoma is further explored.
晚期胰腺癌的系统化疗在临床上常用，但这种疾病的新辅助和辅助治疗的最佳策略仍存在争议。对于那些被认为局部晚期、无法切除或边界可切除的患者，仍然存在一个特殊的挑战。为这群患者提供最佳的新辅助治疗可能会给他们带来根治性手术的机会。本文将讨论新辅助治疗在边界可切除、潜在可切除胰腺癌中的潜在作用。随着胰腺腺癌生物学的进一步探索，还将讨论潜在靶点的关注领域。
